Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled …
CJ Fisher, JFA Dhainaut, SM Opal, JP Pribble, RA Balk… - Jama, 1994 - jamanetwork.com
Objective.—To further define the safety and efficacy of recombinant human interleukin 1
receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design.—
Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial.
Population.—A total of 893 patients with sepsis syndrome received an intravenous loading
dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion
of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure.—Twenty-eight—day …
receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design.—
Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial.
Population.—A total of 893 patients with sepsis syndrome received an intravenous loading
dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion
of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure.—Twenty-eight—day …